Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
TEVJF's Cash to Debt is ranked lower than
91% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. TEVJF: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
TEVJF' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: N/A
Current: 0.08
Equity to Asset 0.47
TEVJF's Equity to Asset is ranked lower than
72% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVJF: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
TEVJF' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.47
0.39
0.6
F-Score: 4
Z-Score: 2.19
M-Score: -2.67
WACC vs ROIC
5.38%
8.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 21.93
TEVJF's Operating margin (%) is ranked higher than
84% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. TEVJF: 21.93 )
Ranked among companies with meaningful Operating margin (%) only.
TEVJF' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.14 Max: 25.46
Current: 21.93
8.12
25.46
Net-margin (%) 8.90
TEVJF's Net-margin (%) is ranked higher than
60% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. TEVJF: 8.90 )
Ranked among companies with meaningful Net-margin (%) only.
TEVJF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 14.73 Max: 20.75
Current: 8.9
5.73
20.75
ROE (%) 7.69
TEVJF's ROE (%) is ranked higher than
52% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TEVJF: 7.69 )
Ranked among companies with meaningful ROE (%) only.
TEVJF' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 11.88 Max: 18.76
Current: 7.69
4.23
18.76
ROA (%) 3.71
TEVJF's ROA (%) is ranked higher than
50% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. TEVJF: 3.71 )
Ranked among companies with meaningful ROA (%) only.
TEVJF' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 6.13 Max: 10.71
Current: 3.71
2.26
10.71
ROC (Joel Greenblatt) (%) 55.14
TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. TEVJF: 55.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVJF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.41  Med: 33.56 Max: 49.79
Current: 55.14
16.41
49.79
Revenue Growth (3Y)(%) 4.80
TEVJF's Revenue Growth (3Y)(%) is ranked lower than
53% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TEVJF: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVJF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 16.55 Max: 23.4
Current: 4.8
4.8
23.4
EBITDA Growth (3Y)(%) 10.70
TEVJF's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. TEVJF: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVJF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 16.05 Max: 47.2
Current: 10.7
-10.5
47.2
EPS Growth (3Y)(%) 4.80
TEVJF's EPS Growth (3Y)(%) is ranked lower than
52% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. TEVJF: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVJF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 16.00 Max: 69.5
Current: 4.8
-25.5
69.5
» TEVJF's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.50
TEVJF's P/E(ttm) is ranked higher than
51% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. TEVJF: 28.50 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s P/E(ttm) Range Over the Past 10 Years
Min: 10.53  Med: 20.47 Max: 1072.29
Current: 28.5
10.53
1072.29
Forward P/E 10.45
TEVJF's Forward P/E is ranked higher than
83% of the 403 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.75 vs. TEVJF: 10.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.40
TEVJF's PE(NRI) is ranked higher than
50% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. TEVJF: 28.40 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.57 Max: 938.25
Current: 28.4
10.53
938.25
P/B 2.21
TEVJF's P/B is ranked higher than
60% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. TEVJF: 2.21 )
Ranked among companies with meaningful P/B only.
TEVJF' s P/B Range Over the Past 10 Years
Min: 1.37  Med: 2.31 Max: 4.81
Current: 2.21
1.37
4.81
P/S 2.62
TEVJF's P/S is ranked higher than
55% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. TEVJF: 2.62 )
Ranked among companies with meaningful P/S only.
TEVJF' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 3.09 Max: 5.86
Current: 2.62
1.58
5.86
PFCF 14.46
TEVJF's PFCF is ranked higher than
82% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.80 vs. TEVJF: 14.46 )
Ranked among companies with meaningful PFCF only.
TEVJF' s PFCF Range Over the Past 10 Years
Min: 8.45  Med: 16.44 Max: 32.92
Current: 14.46
8.45
32.92
POCF 8.92
TEVJF's POCF is ranked higher than
87% of the 631 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.19 vs. TEVJF: 8.92 )
Ranked among companies with meaningful POCF only.
TEVJF' s POCF Range Over the Past 10 Years
Min: 6.56  Med: 12.18 Max: 23.31
Current: 8.92
6.56
23.31
EV-to-EBIT 14.00
TEVJF's EV-to-EBIT is ranked higher than
69% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.51 vs. TEVJF: 14.00 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 12  Med: 19.10 Max: 991
Current: 14
12
991
EV-to-EBITDA 12.10
TEVJF's EV-to-EBITDA is ranked higher than
66% of the 847 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.31 vs. TEVJF: 12.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1  Med: 15.20 Max: 290.6
Current: 12.1
9.1
290.6
PEG 6.04
TEVJF's PEG is ranked lower than
77% of the 278 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. TEVJF: 6.04 )
Ranked among companies with meaningful PEG only.
TEVJF' s PEG Range Over the Past 10 Years
Min: 0.35  Med: 1.49 Max: 135.59
Current: 6.04
0.35
135.59
Shiller P/E 25.60
TEVJF's Shiller P/E is ranked higher than
72% of the 170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.66 vs. TEVJF: 25.60 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s Shiller P/E Range Over the Past 10 Years
Min: 18.72  Med: 34.09 Max: 101.16
Current: 25.6
18.72
101.16
Current Ratio 0.96
TEVJF's Current Ratio is ranked lower than
89% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. TEVJF: 0.96 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 0.96
0.92
2.95
Quick Ratio 0.65
TEVJF's Quick Ratio is ranked lower than
89% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. TEVJF: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.19
Current: 0.65
0.63
2.19
Days Inventory 183.37
TEVJF's Days Inventory is ranked lower than
76% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. TEVJF: 183.37 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 183.37
131.65
208.14
Days Sales Outstanding 96.56
TEVJF's Days Sales Outstanding is ranked lower than
65% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. TEVJF: 96.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 96.56
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.23
TEVJF's Dividend Yield is ranked higher than
71% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TEVJF: 2.23 )
Ranked among companies with meaningful Dividend Yield only.
TEVJF' s Dividend Yield Range Over the Past 10 Years
Min: 0.46  Med: 1.15 Max: 3.26
Current: 2.23
0.46
3.26
Dividend Payout 0.64
TEVJF's Dividend Payout is ranked lower than
78% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TEVJF: 0.64 )
Ranked among companies with meaningful Dividend Payout only.
TEVJF' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.13 Max: 5
Current: 0.64
0.04
5
Dividend Growth (3y) 15.30
TEVJF's Dividend Growth (3y) is ranked higher than
70% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. TEVJF: 15.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TEVJF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.7  Med: 27.85 Max: 80.9
Current: 15.3
-6.7
80.9
Forward Dividend Yield 2.24
TEVJF's Forward Dividend Yield is ranked higher than
68% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVJF: 2.24 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 6.33
TEVJF's Yield on cost (5-Year) is ranked higher than
92% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.86 vs. TEVJF: 6.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVJF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.31  Med: 3.26 Max: 9.25
Current: 6.33
1.31
9.25
3-Year Average Share Buyback Ratio 1.30
TEVJF's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. TEVJF: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVJF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.9  Med: -3.70 Max: 2.6
Current: 1.3
-10.9
2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.04
TEVJF's Price/Projected FCF is ranked higher than
88% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. TEVJF: 1.04 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVJF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.49 Max: 29.19
Current: 1.04
0.6
29.19
Price/DCF (Earnings Based) 0.99
TEVJF's Price/DCF (Earnings Based) is ranked higher than
81% of the 131 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. TEVJF: 0.99 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.81
TEVJF's Price/Median PS Value is ranked higher than
82% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. TEVJF: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.10 Max: 1.89
Current: 0.81
0.52
1.89
Earnings Yield (Greenblatt) (%) 7.10
TEVJF's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVJF: 7.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVJF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 5.20 Max: 8.4
Current: 7.1
0.1
8.4
Forward Rate of Return (Yacktman) (%) 11.76
TEVJF's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. TEVJF: 11.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVJF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9.2  Med: 19.20 Max: 46.2
Current: 11.76
9.2
46.2

More Statistics

Revenue(Mil) $19939
EPS $ 2.07
Beta-0.46
Short Percentage of Float0.00%
52-Week Range $57.25 - 69.24
Shares Outstanding(Mil)852.00

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 19,583 24,324 24,364 25,710
EPS($) 5.29 5.59 5.81 7.15
EPS without NRI($) 5.29 5.59 5.81 7.15

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVJF

Headlines

Articles On GuruFocus.com
Gurus Are Buying High-Yield Stocks Like WestRock, Target Feb 09 2016 
NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical Dec 23 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 
John Paulson Increases Holding in Teva Pharmaceutical Nov 17 2015 
KEELEY All Cap Value Fund Q3 2015 Manager Commentary Nov 03 2015 
Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, NICE Systems Sep 09 2015 
Daniel Loeb's Third Point Second Quarter Investor Letter Aug 03 2015 
Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA Jul 28 2015 
Paul Tudor Jones Buys Stakes in ADP and Visa Jun 19 2015 
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 

More From Other Websites
[$$] Mylan agrees to buy Sweden's Meda for $9.9bn including debt Feb 10 2016
Will Teva (TEVA) Continue with its Earnings Streak in Q4? Feb 10 2016
[$$] Three Best Buys in Specialty Pharma Feb 10 2016
Teva Pharmaceutical (TEVA) Stock Higher Ahead of Thursday’s Earnings Feb 10 2016
Short Sellers Increase Bets in Major Pharma Feb 10 2016
Mylan And Teva Earnings Are Coming: Here's What To Expect Feb 08 2016
The 4 'Momentum Triggers' That Could Give This Biotech Stock 64% Growth Feb 02 2016
Teva Shareholders Shrug Off Latest Collaborative Research Agreement Feb 02 2016
U.S. appeals court ruling may clear barrier to generic OxyContin Feb 01 2016
How Much Is Teva Spending on Research and Development? Jan 29 2016
Antitrust Watchdog: Usual Merger Fix Won't Help Teva's Allergan Deal Jan 29 2016
Insight into Teva’s Over-the-Counter and Distribution Businesses Jan 28 2016
Short Sellers Become More Selective on Major Pharma Jan 28 2016
How Will Teva Finance the Actavis Acquisition? Jan 21 2016
Teva’s Debt Position and Valuations Jan 19 2016
United Therapeutics settles patent dispute with Teva Pharmaceuticals Jan 19 2016
David Einhorn's New Long Position In Mylan Jan 19 2016
Teva’s Generic Segment: What It Looks Like Pre-4Q15 Jan 15 2016
A Close Look at Teva Pharmaceutical’s Specialty Business Jan 15 2016
Analysts Project Dip in Teva Pharmaceutical Revenues in 4Q15 Jan 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK